Search results
Is It Too Late to Buy Pfizer Stock?
Motley Fool via Yahoo Finance· 1 day agoAre Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 2 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Childress Capital Advisors LLC Has $583,000 Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 1 day agoChildress Capital Advisors LLC boosted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 2.2% during the 4th quarter, according to its most recent 13F filing with the Securities ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 2 days agoPfizer disclosed on May 7 that a child participating in another...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 3 days agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 2 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 2 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Former Pfizer Worker’s 401(k) Account Won’t Be Given to Ex-Wife
Bloomberg Law· 22 hours agoemployee can’t access his 401(k) account to satisfy a $75,000 judgment against him in a defamation lawsuit, a Pennsylvania federal judge said. Judge Juan R. Sánchez rejected her request with ...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 3 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 3 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...